...progress with the pembrolizumab biosimilar candidate FYB206. (Formycon Press Release) - Nov 13, 2025 - "Patient recruitment for this ongoing Phase I PK study was already completed in July. Formycon expects results for the primary endpoint in the first quarter of 2026."
P1 data • Melanoma
|